Par Pharmaceutical estimates are inching higher as the company nears its next quarterly report. In addition to a solid earnings history, the company’s strong pipeline has analysts optimistic about the future.
Growth rates are looking good for the Zacks #1 Rank (Strong Buy) but shares are still trading with attractive P/E ratios.
Company Description
Par Pharmaceutical develops, makes and sells generic drugs and some other proprietary pharmaceuticals.
Estimates Rising into Report
One of the best indicators of a strong upcoming quarterly report is rising estimates just ahead of the number. Par is set to announce results on Nov 3 and analysts are upping estimates.
In the past month we have received 3 upward revisions for both this year and next year. The Zacks Consensus Estimate for 2010 is up 4 cents, to $2.50.
No comments:
Post a Comment